PCS-HM190 | 价格

PCS-HM190-100μg / 询价

PCS-HM190-500μg / 询价

PCS-HM190-500μgx2 / 询价

Human PCSK9 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Human PCSK9 Protein is expressed from HEK293 with His tag at the C-Terminus.
It contains Gln31-Gln692 [Accession | Q8NBP7-1].

分子量大小(Molecular Weight)

Due to autocatalytic cleavage, the protein release the pro-form (59 kDa) and mature form (14 kDa). Due to glycosylation, the protein migrates to 65-68 kDa (pro-form) and 15kDa (mature form) based on Bis-Tris PAGE result.

纯度(Purity)

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

制剂(Formulation)

Supplied as 0.22μm filtered solution in 20mM PB, 300mM NaCl, 10% Glycerol (pH 7.4).

存储(Storage)

Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Bis-Tris PAGE

Human PCSK9 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Human PCSK9 is greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized Human PCSK9, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-PCSK9 antibody, hFc Tag with the EC50 of 0.16μg/ml determined by ELISA (QC Test).

SPR Data

Human LDLR, His Tag immobilized on CM5 Chip can bind Human PCSK9, His Tag with an affinity constant of 0.35 nM as determined in SPR assay (Biacore T200).

背景(Background)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and Drug Administration in 2015 for lowering LDL-particle concentrations when statins and other drugs were not sufficiently effective or poorly tolerated.

分子别名(Synonyms)

PC9; PCSK9; FH3; HCHOLA3; LDLCQ1; NARC-1

文献(References)

(1)McKenney, James M. Understanding PCSK9 and anti-PCSK9 therapies[J]. Journal of Clinical Lipidology, 2015, 9(2):170-186.